Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC 5 days ago0CommentsEN NLRead More
Informatiedocument Nieuwe Aandelen – 07 november 2025 November 9, 20250CommentsInformatie betreffende de toelating tot notering en handel op de gereglementeerde markt van Euronext Brussel van 1.000.000.000 nieuwe aandelenRead More
New Shares Information Document – 07 November 2025 November 9, 20250CommentsInformation regarding the admission to listing and trading on the regulated market of euronext brussels of 1,000,000,00 new sharesRead More
Oxurion ends discussions regarding previously announced preclinical transaction and continues integration of a strategic clinical partner November 3, 20250CommentsEN NL FRRead More
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC October 23, 20250CommentsEN NLRead More
Oxurion Receives Amended Transparency Notifications from Atlas Special Opportunities II LLC October 17, 20250CommentsEN NLRead More
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC October 16, 20250CommentsEN NLRead More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas October 15, 20250CommentsEN NLRead More
Oxurion signs letter of intent for the contemplated acquisition of a CRO with strong complementarity to Axiodis October 13, 20250CommentsEN NL FRRead More
Oxurion provides an update related to its investment strategy in digital assets October 9, 20250CommentsEN NL FR Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas October 3, 20250CommentsEN NL Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC October 2, 20250CommentsEN NL Read More
Tussentijdse halfjaarresultaten 30 juni 2025 September 30, 20250CommentsTussentijdse halfjaarresultaten 30 juni 2025Read More
Interim Financial Report Half-year results as of June 30, 2025 September 30, 20250CommentsInterim Financial Report Half-year results as of June 30, 2025Read More
Axiodis CRO, the French subsidiary of the Oxurion Group, announces a dual AI-driven strategic initiative to transform clinical trials September 16, 20250CommentsEN NL FRRead More
Eerste aanvulling op het prospectus van 15 oktober 2024 September 10, 20250CommentsEerste aanvulling op het prospectus van 15 oktober 2024Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC September 8, 20250CommentsEN NL Read More
Oxurion confirms progress in negotiations related to its treasury diversification strategy; closing of the transaction expected before September 25, 2025 September 1, 20250CommentsEN NL FRRead More
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC September 1, 20250CommentsEN NLRead More
